Below are the most recent publications written about "Central Nervous System Agents" by people in Profiles.
-
Di Trana A, Berardinelli D, Montanari E, Berretta P, Basile G, Huestis MA, Busard? FP. Molecular Insights and Clinical Outcomes of Drugs of Abuse Adulteration: New Trends and New Psychoactive Substances. Int J Mol Sci. 2022 Nov 23; 23(23).
-
Hanlon JT, Zhao X, Naples JG, Aspinall SL, Perera S, Nace DA, Castle NG, Greenspan SL, Thorpe CT. Central Nervous System Medication Burden and Serious Falls in Older Nursing Home Residents. J Am Geriatr Soc. 2017 Jun; 65(6):1183-1189.
-
Pomeroy JL, Marmura MJ, Nahas SJ, Viscusi ER. Ketamine Infusions for Treatment Refractory Headache. Headache. 2017 Feb; 57(2):276-282.
-
Silberstein SD. Topiramate in Migraine Prevention: A 2016 Perspective. Headache. 2017 Jan; 57(1):165-178.
-
Bigal ME, Dodick DW, Krymchantowski AV, VanderPluym JH, Tepper SJ, Aycardi E, Loupe PS, Ma Y, Goadsby PJ. TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. Neurology. 2016 Jul 05; 87(1):41-8.
-
Shayan G, Choi YS, Shusta EV, Shuler ML, Lee KH. Murine in vitro model of the blood-brain barrier for evaluating drug transport. Eur J Pharm Sci. 2011 Jan 18; 42(1-2):148-55.
-
Erve JC, Beyer CE, Manzino L, Talaat RE. Metabolite identification in rat brain microdialysates by direct infusion nanoelectrospray ionization after desalting on a ZipTip and LTQ/Orbitrap mass spectrometry. Rapid Commun Mass Spectrom. 2009 Dec; 23(24):4003-12.
-
Stefanacci RG, Cavallaro E, Beers MH, Fick DM. Developing explicit positive beers criteria for preferred central nervous system medications in older adults. Consult Pharm. 2009 Aug; 24(8):601-10.
-
Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, Biondi D, Greenberg SJ, Hulihan J. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009 Mar; 31(3):542-59.
-
Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, Barkhaus PE, Bosch P, Boylan K, David WS, Feldman E, Glass J, Gutmann L, Katz J, King W, Luciano CA, McCluskey LF, Nash S, Newman DS, Pascuzzi RM, Pioro E, Sams LJ, Scelsa S, Simpson EP, Subramony SH, Tiryaki E, Thornton CA. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008 Nov 25; 71(22):1770-5.